Biotech companies saw the most notable insider purchases of the past week. A Mexican billionaire also continued to build a stake.

Last week’s significant news was dominated by licensing deals and mergers and acquisitions. US biotech giant Biogen entered ...

Arcus Biosciences, Inc. (NYSE: RCUS) announced on February 18, 2025, that it has entered into an underwriting agreement with Goldman Sachs & Co. LLC and Leerink Partners LLC for the offering, issuance ...

The pharma signed an agreement handing PE firm CD&R a 50% stake in its Capella unit. Elsewhere, Gilead and Ultragenyx secured ...

The news comes on the heels of promising Phase I/Ib data, which point to the potential of casdatifan as a more effective ...

Arcus Biosciences Inc. (NYSE: RCUS) shares are trading lower Tuesday after the company announced a $150 million common stock ...

Arcus Biosciences (RCUS) stock falls as Gilead (GILD) decides not to buy rights to its anticancer drug casdatifan. Read more here.

Casdatifan targets a transcription factor that binds with other proteins to switch off the body’s anti-inflammatory ...

Arcus Biosciences shares were down 14%, to $11.33, after the company priced a $150 million stock offering. Shares of the biopharmaceutical company hit their 52-week low of $10.65 earlier in the ...

Arcus Biosciences, Inc. has regained ownership of casdatifan, a potential treatment for clear cell renal cell carcinoma (ccRCC), after Gilead’s time-limited exclusive option rights to casdatifan ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Casdatifan’s progression-free survival benefits could help differentiate it from Merck’s Welireg in the kidney cancer arena, ...